CA2135639A1 - Controlled release preparation containing a salt of morphine - Google Patents

Controlled release preparation containing a salt of morphine

Info

Publication number
CA2135639A1
CA2135639A1 CA002135639A CA2135639A CA2135639A1 CA 2135639 A1 CA2135639 A1 CA 2135639A1 CA 002135639 A CA002135639 A CA 002135639A CA 2135639 A CA2135639 A CA 2135639A CA 2135639 A1 CA2135639 A1 CA 2135639A1
Authority
CA
Canada
Prior art keywords
morphine
salt
preparation containing
controlled release
release preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002135639A
Other languages
French (fr)
Other versions
CA2135639C (en
Inventor
Birgitta Olsson
Maritta Anneli Chefrad
Gert Ragnarsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20389415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2135639(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Publication of CA2135639A1 publication Critical patent/CA2135639A1/en
Application granted granted Critical
Publication of CA2135639C publication Critical patent/CA2135639C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Abstract

A new pharmaceutical preparation containing a number of coated particles comprising a salt of morphine coated with a barrier membrane providing a controlled, preferably pH-independent, release of morphine over the main part of the dose interval when administered once daily, providing a significantly reduced plasma concentration fluctuation compared to known morphine preparations. Also disclosed is a method for the manufacture of such a preparation and the use of such preparations for the manufacture of an analgesic useful in the treatment of severe chronical pain.
CA002135639A 1993-03-30 1994-03-24 Controlled release preparation containing a salt of morphine Expired - Lifetime CA2135639C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9301057A SE9301057L (en) 1993-03-30 1993-03-30 Controlled release preparation
SESE9301057-7 1993-03-30
PCT/SE1994/000264 WO1994022431A1 (en) 1993-03-30 1994-03-24 Controlled release preparation containing a salt of morphine

Publications (2)

Publication Number Publication Date
CA2135639A1 true CA2135639A1 (en) 1994-10-13
CA2135639C CA2135639C (en) 2006-02-07

Family

ID=20389415

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002135639A Expired - Lifetime CA2135639C (en) 1993-03-30 1994-03-24 Controlled release preparation containing a salt of morphine

Country Status (25)

Country Link
US (1) US5614218A (en)
EP (1) EP0642335B2 (en)
JP (1) JP4107678B2 (en)
KR (1) KR100316206B1 (en)
CN (1) CN1104891C (en)
AT (1) ATE189771T1 (en)
AU (1) AU680891C (en)
CA (1) CA2135639C (en)
CZ (1) CZ284924B6 (en)
DE (1) DE69423028T3 (en)
DK (1) DK0642335T4 (en)
EE (1) EE03147B1 (en)
ES (1) ES2144516T5 (en)
FI (1) FI113743B (en)
GR (1) GR3033325T3 (en)
HU (1) HU227344B1 (en)
LV (1) LV10684B (en)
NO (1) NO310015B1 (en)
NZ (1) NZ263632A (en)
PL (1) PL175326B1 (en)
PT (1) PT642335E (en)
RU (1) RU2136283C1 (en)
SE (1) SE9301057L (en)
SK (1) SK280362B6 (en)
WO (1) WO1994022431A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
AU735113C (en) * 1991-12-24 2007-06-14 Mundipharma Medical Gmbh Opioid formulations for treating pain
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL109944A (en) † 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19607395C2 (en) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salts from a cationic narcotic analgesic with an anionic non-narcotic analgesic, process for their preparation and the pharmaceutical preparations containing these salts
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
FR2794646B1 (en) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques MORPHINE SULFATE MICROGRANULES, METHOD OF PREPARATION AND COMPOSITION CONTAINING THEM
CN102716101A (en) 1999-10-29 2012-10-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
AU2003270778B2 (en) * 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
MXPA05003513A (en) * 2002-10-04 2005-06-03 Pharmacia Corp Pharmaceutical compositions for treatment of parkinson's disease.
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
ATE495732T1 (en) 2003-03-26 2011-02-15 Egalet As CONTROLLED RELEASE MORPHINE SYSTEM
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
JP2007521231A (en) * 2003-08-08 2007-08-02 バイオヴェイル ラボラトリーズ インコーポレイテッド Controlled release tablets of bupropion hydrochloride
EP1810678A1 (en) 2006-01-19 2007-07-25 Holger Lars Hermann Use of morphine and naloxone for drug substitution
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2008011596A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
ES2692437T3 (en) * 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Abuse-resistant drugs, method of use and method of preparation
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
EP2590636A1 (en) 2010-07-06 2013-05-15 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
KR20150059167A (en) 2012-07-06 2015-05-29 에갈렛 리미티드 Abuse deterrent pharmaceutical compositions for controlled release
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
ES2809458T3 (en) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Liquid filled, abuse deterrent and immediate release dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
JP2017531026A (en) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Sustained release abuse deterrent liquid filler form

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (en) * 1981-11-20 1987-05-25 Benzon As Alfred PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
SE8902699D0 (en) * 1989-08-09 1989-08-09 Lejus Medical Ab DILTIAZEM CONTAINING PHARMACEUTICAL COMPOSITIOS
DE4105480A1 (en) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh IMPROVED ACTIVATION OF RECOMBINANT PROTEINS
US5273760A (en) † 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) † 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
SE9202250D0 (en) * 1992-07-29 1992-07-29 Gacell Lab Ab CONTROLLED RELEASE MORPHINE PREPARATION

Also Published As

Publication number Publication date
CZ284924B6 (en) 1999-04-14
DK0642335T3 (en) 2000-07-24
ES2144516T5 (en) 2005-07-01
RU2136283C1 (en) 1999-09-10
CZ298694A3 (en) 1995-05-17
CN1106608A (en) 1995-08-09
EP0642335A1 (en) 1995-03-15
DE69423028T2 (en) 2001-01-18
EP0642335B1 (en) 2000-02-16
AU680891C (en) 2002-01-03
SK280362B6 (en) 1999-12-10
SE9301057L (en) 1994-10-01
DE69423028D1 (en) 2000-03-23
KR100316206B1 (en) 2002-11-09
SK143794A3 (en) 1995-06-07
DE69423028T3 (en) 2006-07-20
HUT71417A (en) 1995-11-28
LV10684B (en) 1996-02-20
HU9403437D0 (en) 1995-02-28
ES2144516T3 (en) 2000-06-16
WO1994022431A1 (en) 1994-10-13
AU680891B2 (en) 1997-08-14
AU6439394A (en) 1994-10-24
NO310015B1 (en) 2001-05-07
LV10684A (en) 1995-06-20
NO944565D0 (en) 1994-11-29
PL175326B1 (en) 1998-12-31
PL306421A1 (en) 1995-04-03
JPH08501319A (en) 1996-02-13
SE9301057D0 (en) 1993-03-30
PT642335E (en) 2000-08-31
EP0642335B2 (en) 2005-01-19
FI113743B (en) 2004-06-15
CN1104891C (en) 2003-04-09
ATE189771T1 (en) 2000-03-15
EE03147B1 (en) 1999-02-15
NO944565L (en) 1994-11-29
RU94046147A (en) 1996-11-10
FI945621A (en) 1994-11-29
JP4107678B2 (en) 2008-06-25
GR3033325T3 (en) 2000-09-29
HU227344B1 (en) 2011-04-28
NZ263632A (en) 1997-06-24
US5614218A (en) 1997-03-25
FI945621A0 (en) 1994-11-29
DK0642335T4 (en) 2005-05-23
CA2135639C (en) 2006-02-07

Similar Documents

Publication Publication Date Title
CA2135639A1 (en) Controlled release preparation containing a salt of morphine
NZ508526A (en) Opioid formulations for treating pain
CA2166108A1 (en) Insulin preparations for inhalation
AU2326892A (en) Acylmercaptoalkanoyldipeptides, methods of preparation and their therapeutic use
CA2098738A1 (en) Controlled Release Oxycodone Compositions
AU1534699A (en) Osmotic dosage form comprising first and second coats
AU4359096A (en) An inhalation device, a method of dispersing a pharmaceutically active substance and a method of administering a dose of pharmaceutically active substance
GEP20002229B (en) Synthetic Membrane Vesicles, Method for Obtaining and Application of the Same
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
GEP19991686B (en) Pharmaceutical Composition for Obtaining Effervescent Powder or Tablet, Pharmaceutical Preparation and Method for Preparing Same
AU7239996A (en) Inhibition of tumor necrosis factor alpha
MY124465A (en) Reduction of infarct volume using citicoline
AU3257993A (en) 3-methylsulphonylhydrazono and 3-oxyimino steroids, a method of preparing them, pharmaceutical preparations containing them and their use in the preparation of drugs
ZA961050B (en) Substituted benzenesulfonylureas and -thioureas processes for their preparation their use for the production of pharmaceutical preparations and pharmaceutical preparations containing them
AU4555996A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them
CA2122344A1 (en) Liposome preparation containing tricyclic compound
IL117179A0 (en) Substituted benzenesulfonylureas and -thioureas processes for their preparation and use of pharmaceutical preparations based on these compounds and medicaments containing them
AU1447892A (en) Pharmaceutical preparations for the therapy of tumors containing colchicine as the active principle and methods for the use of the same
ZA961232B (en) Substituted benzenesulfonylureas and -thioureas processes for their preparation and use of pharmaceutical preparations based on these compounds and medicaments containing them
RU95100741A (en) Method of lung tuberculosis treatment
MY110769A (en) Controlled release oxycodone compositions.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140324